FindTrial
Sign In

Effect and Efficacy of Plant-Derived Ceramide Moisturizer in Psoriasis Vulgaris

Effect and Efficacy of Plant-Derived Ceramide Moisturizer as an Adjunctive and Maintenance Therapy in the Treatment of Psoriasis Vulgaris: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-14004188
Enrollment
Unknown
Registered
2014-01-17
Start date
2003-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis Vulgaris

Interventions

Control Group (C1):mometasone furoate 0.1% cream (Eloson) once daily
Treatment Group (T1):mometasone furoate 0.1% cream (Eloson) once daily +Plant Derived Ceramide moisturizer
Control Group (C2):mometasone furoate 0.1% cream (Eloson) prn
Treatment Group (T2):Plant Derived Ceramide moisturizer once daily,mometasone furoate 0.1% cream (Eloson) prn

Sponsors

Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Clinically Diagnosed Psoriasis Vulgaris patients; 2. Aged between 12-85 years old; 3. No limitation on gender; 4. Participant or legal guardian fully understands the content of the clinical trial, is willing to attend the research voluntary and sign the informed consent form; 5. Physical examination is qualified, participant does not have previous severe systemic disease.

Exclusion criteria

Exclusion criteria: 1. physical examination failed to qualify for enrollment; 2. during gestational and lactation period; 3. known allergic history toward drug or moisturizer under study; 4. involved in any other clinical trial three months before enrollment; 5. frequently usage of herbal, hypnotics, sedative, stabilizers, or other addictive medication; 6. alcoholics, psychotic, or participants who cannot follow prescription order; 7. Utilization of any types of skin moisturizers or topical medications within one-month prior to the screening and during the study period; 8. systemic therapies or phototherapy previously within three months of screening and during the study period.

Design outcomes

Primary

MeasureTime frame
Normal skin capacitance;Lesional skin capacitance;Normal skin transepidermal water loss;Lesional skin transepidermal water loss;Pruritus;Psoriasis Area Severity Index (PASI);PASI-50 Efficacy indix;PASI 50% Relapse indix;PASI 125% Rebound indix;—

Countries

China

Contacts

Public ContactJie Zheng

Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

jie-zheng2001@126.com+86 18917762309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026